{
    "clinical_study": {
        "@rank": "16766", 
        "arm_group": {
            "arm_group_label": "LGH447", 
            "arm_group_type": "Experimental", 
            "description": "Single arm study dosed with LGH447"
        }, 
        "brief_summary": {
            "textblock": "This study will assess the safety and preliminary efficacy of escalating doses of LGH447 in\n      AML and MDS."
        }, 
        "brief_title": "A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "AML and High Risk MDS", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Relapsed/refractory AML following no more than 2 prior therapies or in AML patient\n             for whom no effective therapy exists; or high and very high risk MDS\n\n          -  For AML patients, peripheral blast counts < 50,000 blasts/mm3\n\n          -  For MDS patients;\n\n               -  Platelet count > 25,000/mm3\n\n               -  Neutrophils > 500/mm3\n\n               -  Blood transfusions are allowed to maintain clinically adequate hemoglobin and\n                  hematocrit levels\n\n          -  Patients with active central nervous system (CNS) disease are eligible to participate\n             and may be treated concurrently with intrathecal (or intra Ommaya) chemotherapy\n\n          -  Patients who are maintained on prophylactic antibiotics are eligible to participate\n             as long as agents comply with the list of approved concomitant medications\n\n             -\u2265 18 year old\n\n          -  Performance status \u2264 2\n\n          -  Meet other lab criteria\n\n        Exclusion criteria:\n\n          -  Systemic antineoplastic therapy (including unconjugated therapeutic antibodies and\n             toxin immunoconjugates) or any experimental therapy within 7 days or 5 half-lives,\n             whichever is longer, before the first dose of LGH447\n\n          -  Radiotherapy with a wide field of radiation within 28 days or radiotherapy with a\n             limited field of radiation for palliation within 7 days of the first dose of LGH447\n\n          -  Patients who received CNS irradiation for meningeal leukemia, except if radiotherapy\n             occurred > 3 months previously\n\n          -  Major surgery within 4 weeks before the first dose of LGH447\n\n          -  Ongoing therapy with corticosteroids greater than 10 mg of prednisone or its\n             equivalent per day. Inhaled and topical steroids are permitted\n\n          -  Patients who are currently receiving hydroxyurea to control peripheral blood leukemic\n             blasts and cannot be discontinued for at least 48 hours prior to obtaining PD\n             biomarkers at screening/baseline and during the study\n\n          -  Patients who are currently receiving treatment with prohibited medication and that\n             cannot be discontinued at least one week prior to the start of treatment with LGH447\n\n          -  Active infection requiring systemic therapy or other severe infection, including\n             pneumonia, within 2 weeks before the first dose of LGH447.\n\n          -  Known human immunodeficiency virus (HIV) positive\n\n          -  Corrected QT interval (QTc) of > 450 milliseconds (ms) in males and > 470\n             milliseconds (ms) in females on baseline electrocardiogram (ECG) (using corrected QT\n             interval using Fridericia [QTcF] or local standards).\n\n          -  Uncontrolled cardiovascular condition, including ongoing cardiac arrhythmias,\n             congestive heart failure, angina, or myocardial infarction within the past 6 months\u2014\n\n          -  Pregnant or nursing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02078609", 
            "org_study_id": "CLGH447X2102", 
            "secondary_id": "2013-003756-20"
        }, 
        "intervention": {
            "arm_group_label": "LGH447", 
            "intervention_name": "LGH447", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "AML,", 
            "MDS,", 
            "PIM,", 
            "LGH447,", 
            "acute myelod leukemia,", 
            "myelodysplastic syndrome"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "contact": {
                    "email": "tpelton@med.umich.edu", 
                    "last_name": "Tina P. Willbee", 
                    "phone": "734-936-3879"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109-0944"
                    }, 
                    "name": "University of Michigan Comprehensive Cancer Center Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Dale Bixby", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prahran", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3181"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13273"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany", 
                        "zip": "89081"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM", 
                        "zip": "00133"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1081 HV"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "France", 
                "Germany", 
                "Italy", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Multicenter, Open-label Study of Oral LGH447 in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "France: Agence Nationale de Securit\u00e9 du m\u00e9dicament", 
                "Germany: The Federal Institute for Drugs and Medical Devices (BfArM)", 
                "Italy: Ministry of Labor, Health & Social Affairs, Department of Innovation", 
                "Netherlands: Dutch Healthcare Inspectorate (IGZ)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Frequency and characteristics of dose limiting toxicities", 
            "measure": "Incidence rate of dose limiting toxicities (DLTs)", 
            "safety_issue": "Yes", 
            "time_frame": "30 days post study treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02078609"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Includes changes in hematology and blood chemistry values, assessments of physical examinations, vital signs, and electrocardiograms (ECGs)", 
                "measure": "Number of participants with the type, frequency, and severity of adverse events (AEs) as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "weekly to bi-weekly up to 1.5 years"
            }, 
            {
                "description": "LGH447 plasma concentrations and basic PK parameters", 
                "measure": "PK parameters including but not limited to Cmax, Cmin, AUCinf, AUCtlast, AUCtau and T1/2", 
                "safety_issue": "No", 
                "time_frame": "days 1, 2, 15, 16, 29, 30, 44, 57, and approximately monthly up to 1.5 years"
            }, 
            {
                "description": "Assess pharmacodynamic effects of LGH447", 
                "measure": "Changes between pre- and post-treatment levels of pS6RP and p4EBP1 in bone marrow aspirates and p4EBP1 in peripheral blood", 
                "safety_issue": "No", 
                "time_frame": "screening, days 1 and 29 up to 1.5 years"
            }, 
            {
                "description": "To assess clinical response associated with LGH447 which includes Complete Response (CR), Complere Response in incomplete blood count (CRi), Partial Response (PR), Best Overall Response (BOR), Duration of Response (DoR), Time to Progression (TTP).", 
                "measure": "Changes in pre- and post-treatment levels of leukemic blasts in the peripheral blood and bone marrow and normal cells in the peripheral blood", 
                "safety_issue": "No", 
                "time_frame": "approximately monthly up to 1.5 years"
            }, 
            {
                "description": "To assess clinical response associated with LGH447 which includes Complete Response (CR), bone marror CR, Partial Response (PR), Hematologic response-Erythroid, platelet, neutrophil (HI-E,P, N), Best Overall Response (BOR), Duration of Response (DoR), Time to Progression (TTP), Progression Free Survival (PFS).", 
                "measure": "Changes in pre- and post-treatment levels of leukemic blasts in the peripheral blood and bone marrow and normal cells in the peripheral blood", 
                "safety_issue": "No", 
                "time_frame": "approximately monthly up to 1.5 years"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}